Board of Directors

Donald J. McCaffreyChairman of the Board

Mr. McCaffrey is the co-founder, President and CEO of Zenith Capital Corp., a biotechnology investment company focused on the discovery and development of novel therapeutics for the treatment of cancer and other disorders with significant unmet medical need. Zenith was spun out of Resverlogix Corp. (TSX: RVX) in 2013.

Don has over 38 years of corporate management experience including over 18 years in drug discovery & development. Don’s expertise in corporate operations has attracted an international team of experts to the company, including world renowned Key Opinion Leaders in the fields of oncology.

In addition to Zenith, Don serves as President, CEO and Chairman of Resverlogix Corp. (TSX: RVX), a pioneer in the landscape of epigenetics, currently conducting a global Phase 3 clinical trial – BETonMACE – with the most advanced epigenetic drug outside of oncology, apabetalone.

Don’s career accomplishments have been recognized by the business community and peers, as he was nominated for Ernst & Young Entrepreneur of the Year three times. He has also arranged support for several non-profit organizations, including: the Libin Cardiovascular Institute of Alberta, Juvenile Diabetes Research Foundation, Sanofi Biogenius Canada (MindFuel), United Way, Mount Royal University Foundation, Alberta Children's Hospital, Edge School Foundation, Education Matters, Calgary Urban Project Society Literacy Program, Movember Foundation, and Enbridge Ride to Conquer Cancer.

Kelly McNeill, B.COMM (HONS), M.ACC, C.A.Director

Mr. McNeill is currently the Chief Financial Officer at RTDS Technologies Inc., a global provider of real time digital simulators to the power systems industry, with an install base of over 1100 units in 37 countries. Prior to joining RTDS, Mr. McNeill was the Executive Vice President, Finance and Administration and Chief Financial Officer of IMRIS Inc. from 2009 through 2014.  In that role, he was responsible for leading the financial operations of the Company including M&A, capital management including a NASDAQ IPO, and its relocation of its operations from Canada to the U.S. to support its development in the advanced surgical imaging solutions field.  Prior to joining IMRIS, Kelly was part of Resverlogix's Senior Management Team from 2006 to 2009 as its Chief Financial Officer, where he was responsible for overseeing corporate finance, financial reporting, and human resources.

Prior to Resverlogix, Mr. McNeill worked at Haworth and SMED International in Calgary Alberta in the office interiors industry, serving in various management positions including the General Manager of the Canadian operations for Haworth and Vice President of Finance for SMED.  During his 9 year tenure, Mr. McNeill was part of a NASDAQ IPO and the sale of SMED to Haworth, a global office furniture manufacturer headquartered in Michigan, for $240 million. 

Mr. McNeill has nearly 20 years of experience in manufacturing and technology organizations, both large and small, with experience in M&A, raising capital in public equity markets, and managing complex operations around the globe. 

Mr. McNeill is a chartered accountant and earned a B.Comm (Hons) and M.Acc from the University of Manitoba. In addition to Zenith Epigenetics Corp., he also serves as a member of the Board of Directors for Resverlogix Corp.

Dr. Eldon R. Smith OC, MD, FRCPC, FCAHS, FAHA, FIACSDirector

From 1992 to 1997, Dr. Smith was Dean of the Faculty of Medicine at the University of Calgary.  From 1997 until 2010, he has been Editor-in-Chief of the Canadian Journal of Cardiology.  Dr. Smith’s research interests include circulatory mechanics, exercise physiology and echocardiography.  He has published more than 250 papers and book chapters and has been a contributor to many national and international organizations; he has been President of the Canadian Cardiovascular Society and the Association of Canadian Medical Colleges and Vice President of the Inter-American Society of Cardiology.  He has served on a number of public boards including the Alberta Heritage Foundation for Medical Research, the Alberta Health Professions Advisory Board, and the Premier’s Advisory Council on Health in Alberta. He founded and served as President and Director of the Peter Lougheed Medical Research Foundation, a national initiative to support excellence in health research in Canada. He is chair of the Advisory Board of the Libin Cardiovascular Institute of Alberta and from 2006 to 2010 he was appointed by the Federal Government to chair the development of a National Strategy for Cardiovascular Health and Disease.

In addition to Zenith Epigenetics Corp., Dr. Smith currently serves on the Boards of Resverlogix Corp., Canadian Natural Resources Ltd, Intellipharmaceutics International Inc., and Aston Hill Financial.

Dr. Norman C.W. Wong, M.D., FRCPDirector

Dr. Wong is Chief Scientific Officer and co-founder of Resverlogix Corp. Dr. Wong's research interest focuses on the molecular actions of hormones related to the regulation of lipoprotein expression and pathogenesis of diabetes mellitus.  These topics of interest involved studies of chromatin structure, gene regulation and transcription factors which are major components of epigenetics.  His clinical interest encompasses patients with thyroid disease including thyroid cancer or diabetes mellitus. His most recent successes have come from elucidating the potential therapeutic opportunities for cardiovascular disease by harnessing the regulation of Apolipoprotein A-I (ApoA-I) gene expression using inhibition of BET-proteins that play important roles in epigenetics.

Dr. Wong keeps active in the academic community by participating in speaking engagements at national and international medical conferences. He has been the author and co-author of more than 275 articles and abstracts and has been invited to sit on more than 40 national or international panels and committees. He has also acted as a consultant to several leading pharmaceutical companies, including Eli Lilly, Merck Frost, GlaxoSmithKline, Solvay Pharmaceuticals and Abbott Laboratories.

Kenneth J. ZuerblisDirector

Mr. Zuerblis was formerly Executive Vice President and Chief Financial Officer of Savient Pharmaceuticals, Inc., a position he held until May 2012. Prior to joining Savient, Mr. Zuerblis served as Chief Financial Officer and Senior Vice President at ImClone Systems from 2008 through 2009. In that role, he was responsible for the strategic planning and leadership of finance and related operations and helped lead all aspects of the sale of the company to Eli Lilly and Company. From 1994 through 2005, Mr. Zuerblis served as Chief Financial Officer of Enzon Pharmaceuticals Inc., and held the position of Corporate Controller from 1991 through 1994. Enzon developed the first three FDA approved products using PEGylation technology. Most notably during Mr. Zuerblis’ 14 year tenure, Enzon transformed from an early stage biotechnology company into a fully integrated biopharmaceutical company with five marketed products.

He began his career at KPMG, LLP in 1982 where he held management positions of increasing responsibility over a 10 year period. Mr. Zuerblis brings nearly 30 years of proven leadership expertise in building fully integrated biopharmaceutical organizations and has an established track record of managing complex commercial and research organizations, raising capital, overseeing multifaceted merger and acquisition transactions, and directing all investor and shareholder relations.

Mr. Zuerblis earned his Bachelor of Science in Accounting from Seton Hall University and is a certified public accountant in the State of New Jersey.

Mr. Zuerblis is currently a member of the Board of Directors of Zenith Epigenetics Corp., Resverlogix Corp. and Stemline Therapeutics.